Best Value Stocks To Own For 2018

The Q4 2016 earnings report for small cap cancer stock Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is scheduled for before the market opens on Wednesday (March 1st). In early January, Merrimack Pharmaceuticals reportedadefinitive asset purchase and sale agreement with Ipsen SA (EPA: IPN; IPSEY) for a transaction valued at up to $1.025 billion (plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire) under which Merrimack will:

Sell to Ipsen its first commercial product ONIVYDE庐, including U.S. commercialization rights and its licensing agreement with Shire plc; and Sell to Ipsen its generic version of doxorubicin hydrochloride (HCI) liposome injection (“generic DOXIL庐”) marketed in the United States as DOXIL庐 and advanced under a development, license and supply agreement with Actavis LLC.

Upon completing the Ipsen transaction and refocusing effort, the Company will have approximately 80 employees for a reduction of 80% from approximately 400 employees prior to implementing the restructuring in October 2016.

Best Value Stocks To Own For 2018: Smart(SFS)

Advisors’ Opinion:

  • [By Shane Hupp]

    Smart & Final (NYSE: SFS) and Kroger (NYSE:KR) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

Best Value Stocks To Own For 2018: Uranium Resources, Inc.(URRE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Uranium Resources, Inc. (NASDAQ: URRE) was down, falling around 12 percent to $2.37 after the company reported a closing of $9.7 million public offering.

  • [By Lisa Levin]

    Uranium Resources, Inc. (NASDAQ: URRE) shares dropped 19 percent to $2.55 after the company reported the pricing of $9.7 million public offering.

Best Value Stocks To Own For 2018: Noah Holdings Ltd.(NOAH)

Advisors’ Opinion:

  • [By Monica Gerson]

    Noah Holdings Limited (ADR) (NYSE: NOAH) is estimated to post financial results for its latest quarter.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Best Value Stocks To Own For 2018: Impax Laboratories, Inc.(IPXL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Impax Laboratories Inc (NASDAQ: IPXL) were down around 29 percent to $10.12. Impax Labs reported Q4 adjusted earnings of $0.16 per share on revenue of $198.4 million.

  • [By Keith Speights]

    Impax Laboratories (NASDAQ: IPXL  ) could be watching more closely than Sanofi. The two companies reached a deal last year that allows Impax to begin marketing a generic version of Renvela in 2014. If approved, Zerenex could take away some of the profits that Impax expected to gain.

Best Value Stocks To Own For 2018: Cherokee Inc.(CHKE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Cherokee Inc (NASDAQ: CHKE) shares dropped 32 percent to $5.26 after the company reported a loss for its first quarter on Thursday. The company reported an adjusted loss of $0.07 per share, versus analysts’ estimates for a profit of $0.13 per share.

  • [By Lisa Levin]

    Cherokee Inc (NASDAQ: CHKE) shares dropped 37 percent to $4.85 after the company reported a loss for its first quarter on Thursday. The company reported an adjusted loss of $0.07 per share, versus analysts’ estimates for a profit of $0.13 per share.

  • [By Max Byerly]

    Cherokee (NASDAQ: CHKE) and J.Jill (NYSE:JILL) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Leave a Reply

Your email address will not be published. Required fields are marked *